Drug Profile
Becaplermin biosimilar - Adocia
Alternative Names: BC-PDGF-BB; BioChaperone® PDGF-BB; PDGF-BB biosimilar - AdociaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Adocia
- Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
- Mechanism of Action Platelet-derived growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Burns; Diabetic foot ulcer; Pressure ulcer; Varicose ulcer
Highest Development Phases
- Discontinued Burns; Diabetic foot ulcer; Pressure ulcer; Varicose ulcer
Most Recent Events
- 22 Sep 2016 Discontinued - Phase-III for Diabetic foot ulcer in India (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Burns in France (Topical, Spray)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pressure-ulcer in France (Topical, Spray)